Skip to main content
Premium Trial:

Request an Annual Quote

William Annett

William Annett has been appointed CEO of OncoCyte, succeeding Joseph Wagner who led the firm in the early stages of clinical development of its products. Annett has been a member of OncoCyte's board since January, and he previously served as managing director at Accenture. He was also CEO of BioFX Laboratories and founded and led Corra Life Sciences. 

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.